• 1
    Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials [review]. JAMA 1997; 278: 31321.
  • 2
    Pedersen TR. Statin trials and goals of cholesterol-lowering therapy after AMI [review]. Am Heart J 1999; 138: S17782.
  • 3
    Vaughan CJ, Gotto AM Jr, Basson CT. The evolving role of statins in the management of atherosclerosis [review]. J Am Coll Cardiol 2000; 35: 110.
  • 4
    Palinski W. New evidence for beneficial effects of statins unrelated to lipid lowering [editorial]. Arterioscler Thromb Vasc Biol 2001; 21: 35.
  • 5
    Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001; 21: 11521.
  • 6
    Inoue I, Goto S, Mizotani K, Awata T, Mastunaga T, Kawa S, et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor α (PPARα) in primary endothelial cells. Life Sci 2000; 67: 86376.
  • 7
    Zelvyte I, Dominaitiene R, Crisby M, Janciauskiene S. Modulation of inflammatory mediators and PPARγ and NFκB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res 2002; 45: 14754.
  • 8
    Romano M, Diomede L, Sironi M, Massimiliano L, Sottocorno M, Polentarutti N, et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 2000; 80: 1095100.
  • 9
    Weber C, Erl W, Weber KS, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997; 30: 12127.
  • 10
    Wong B, Lumma WC, Smith AM, Sisko JT, Wright SD, Cai TQ. Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. J Leukoc Biol 2001; 69: 95962.
  • 11
    Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 2003; 23: 76975.
  • 12
    Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399402.
  • 13
    Sadeghi MM, Tiglio A, Sadigh K, O'Donnell L, Collinge M, Pardi R, et al. Inhibition of interferon-γ-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors. Transplantation 2001; 71: 12628.
  • 14
    Schonbeck U, Gerdes N, Varo N, Reynolds RS, Horton DB, Bavendiek U, et al. Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation 2002; 106: 288893.
  • 15
    Wagner AH, Gebauer M, Guldenzoph B, Hecker M. 3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells. Arterioscler Thromb Vasc Biol 2002; 22: 17849.
  • 16
    Mulhaupt F, Matter CM, Kwak BR, Pelli G, Veillard NR, Burger F, et al. Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc Res 2003; 59: 75566.
  • 17
    Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7: 68792.
  • 18
    Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101: 20713.
  • 19
    Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420: 7884.
  • 20
    Aktas O, Waiczies S, Smorodchenko A, Dorr J, Seeger B, Prozorovski T, et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med 2003; 197: 72533.
  • 21
    Stanislaus R, Pahan K, Singh AK, Singh I. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci Lett 1999; 269: 714.
  • 22
    Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358: 90311.
  • 23
    Harris ED Jr. Rheumatoid arthritis: pathophysiology and implications for therapy [published erratum appears in N Engl J Med 1990;323:996]. N Engl J Med 1990; 322: 127789.
  • 24
    Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis [review]. N Engl J Med 2001; 344: 90716.
  • 25
    Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, Payne H, et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003; 170: 152430.
  • 26
    Sipe JD, Gonnerman WA, Loose LD, Knapschaefer G, Xie WJ, Franzblau C. Direct binding enzyme-linked immunosorbent assay (ELISA) for serum amyloid A (SAA). J Immunol Methods 1989; 125: 12535.
  • 27
    Walker CD, Sizonenko PC, Aubert ML. Modulation of the neonatal pituitary and adrenocortical responses to stress by thyroid hormones in the rat: effects of hypothyroidism and hyperthyroidism. Neuroendocrinology 1989; 50: 26573.
  • 28
    Landmann S, Muhlethaler-Mottet A, Bernasconi L, Suter T, Waldburger JM, Masternak K, et al. Maturation of dendritic cells is accompanied by rapid transcriptional silencing of class II transactivator (CIITA) expression. J Exp Med 2001; 194: 37991.
  • 29
    Mooser V, Berger MM, Tappy L, Cayeux C, Marcovina SM, Darioli R, et al. Major reduction in plasma Lp(a) levels during sepsis and burns. Arterioscler Thromb Vasc Biol 2000; 20: 113742.
  • 30
    Endo A, Tsujita Y, Kuroda M, Tanzawa K. Effects of ML-236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in normal animals. Biochim Biophys Acta 1979, 575: 26676.
  • 31
    Kita T, Brown MS, Goldstein JL. Feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase. J Clin Invest 1980; 66: 1094100.
  • 32
    Kiener PA, Davis PM, Murray JL, Youssef S, Rankin BM, Kowala M. Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. Int Immunopharmacol 2001; 1: 10518.
  • 33
    Sun D, Fernandes G. Lovastatin inhibits bone marrow-derived dendritic cell maturation and upregulates proinflammatory cytokine production. Cell Immunol 2003; 223: 5262.
  • 34
    Ueno M, Imaizumi K, Sugita T, Takata I, Takeshita M. Effect of a novel anti-rheumatic drug, TA-383, on type II collagen-induced arthritis. Int J Immunopharmacol 1995; 17: 597603.
  • 35
    Ishikaw J, Okada Y, Bird IN, Jasani B, Spragg JH, Yamada T. Use of anti-platelet-endothelial cell adhesion molecule-1 antibody in the control of disease progression in established collagen-induced arthritis in DBA/1J mice. Jpn J Pharmacol 2002; 88: 33240.
  • 36
    Sena A, Pedrosa R, Graca Morais M. Therapeutic potential of lovastatin in multiple sclerosis [letter]. J Neurol 2003; 250: 7545.
  • 37
    Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis [comment]. Lancet 2004; 363: 16078.
  • 38
    McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, et al. Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004; 363: 201521.